Matches in Wikidata for { <http://www.wikidata.org/entity/Q91889126> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- Q91889126 description "2019 թվականի դեկտեմբերի 10-ին հրատարակված գիտական հոդված" @default.
- Q91889126 description "article scientifique publié en 2019" @default.
- Q91889126 description "artículu científicu espublizáu n'avientu de 2019" @default.
- Q91889126 description "im Dezember 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q91889126 description "scientific article published on 10 December 2019" @default.
- Q91889126 description "wetenschappelijk artikel" @default.
- Q91889126 description "наукова стаття, опублікована 10 грудня 2019" @default.
- Q91889126 name "A prospective, open-label, interventional study protocol to evaluate treatment efficacy of nivolumab based on serum-soluble PD-L1 concentration for patients with metastatic and unresectable renal cell carcinoma" @default.
- Q91889126 name "A prospective, open-label, interventional study protocol to evaluate treatment efficacy of nivolumab based on serum-soluble PD-L1 concentration for patients with metastatic and unresectable renal cell carcinoma" @default.
- Q91889126 type Item @default.
- Q91889126 label "A prospective, open-label, interventional study protocol to evaluate treatment efficacy of nivolumab based on serum-soluble PD-L1 concentration for patients with metastatic and unresectable renal cell carcinoma" @default.
- Q91889126 label "A prospective, open-label, interventional study protocol to evaluate treatment efficacy of nivolumab based on serum-soluble PD-L1 concentration for patients with metastatic and unresectable renal cell carcinoma" @default.
- Q91889126 prefLabel "A prospective, open-label, interventional study protocol to evaluate treatment efficacy of nivolumab based on serum-soluble PD-L1 concentration for patients with metastatic and unresectable renal cell carcinoma" @default.
- Q91889126 prefLabel "A prospective, open-label, interventional study protocol to evaluate treatment efficacy of nivolumab based on serum-soluble PD-L1 concentration for patients with metastatic and unresectable renal cell carcinoma" @default.
- Q91889126 P1433 Q91889126-C7CACC22-B63D-41AC-8082-D01AA7679831 @default.
- Q91889126 P1476 Q91889126-F5C43734-9DB7-49B6-A4CC-90AFD6A99C48 @default.
- Q91889126 P2093 Q91889126-11DCE34C-757C-4638-962D-CD695EF1DBC1 @default.
- Q91889126 P2093 Q91889126-3CBB6CFD-D682-4B67-B769-3450A5FBB542 @default.
- Q91889126 P2093 Q91889126-414A3130-48FE-4DAE-8537-17B4604F00D5 @default.
- Q91889126 P2860 Q91889126-2C83BD6D-302A-41CA-91EB-913B8C8E2D9B @default.
- Q91889126 P2860 Q91889126-2D3BD142-A1D5-43F7-980D-95CE26EAC630 @default.
- Q91889126 P2860 Q91889126-4C571EE9-653A-41B0-BC94-C86168D96BF6 @default.
- Q91889126 P2860 Q91889126-56CC5202-7D2D-4654-99DA-77412E054479 @default.
- Q91889126 P2860 Q91889126-666989C5-6C0A-4F62-A48C-A90B6563E5CE @default.
- Q91889126 P2860 Q91889126-68698CD5-E64E-4BF5-B602-EC36FC4CCF6A @default.
- Q91889126 P2860 Q91889126-7D75B684-88AA-457F-A3BD-6AF4B921237E @default.
- Q91889126 P2860 Q91889126-8DD2642B-618A-4A2D-A591-FEC60D450F0C @default.
- Q91889126 P2860 Q91889126-BB0F163C-E7A0-4A57-B19C-D41897218176 @default.
- Q91889126 P2860 Q91889126-ECE056D9-2128-47BA-96C9-C88EF2989099 @default.
- Q91889126 P304 Q91889126-41159758-4202-4CCA-8884-81EA8246A360 @default.
- Q91889126 P31 Q91889126-B1777BEB-F014-4621-858D-C78C204BDB46 @default.
- Q91889126 P356 Q91889126-FD125F53-2517-473F-8692-31B268D2534D @default.
- Q91889126 P433 Q91889126-76DF8136-2480-4FC4-AA79-76CDCB96F1EC @default.
- Q91889126 P478 Q91889126-E7EBC8D5-17F7-4433-8AC9-3C17779ADCDE @default.
- Q91889126 P50 Q91889126-ED6E783E-57DC-4C4D-B5F2-B81D2E61C58A @default.
- Q91889126 P577 Q91889126-766F81D6-B4BB-4347-B221-4D0ECDC1A1C0 @default.
- Q91889126 P698 Q91889126-529B972E-571E-401B-9E45-7A9EF29CFFE4 @default.
- Q91889126 P921 Q91889126-82C845E6-71DF-4FE2-8097-FA0668F3B06D @default.
- Q91889126 P921 Q91889126-D8A5D42F-C8F0-4D2E-961D-B2C2E8148A04 @default.
- Q91889126 P932 Q91889126-9911B67E-71F6-4952-974B-F9AD43771AA4 @default.
- Q91889126 P356 BMJOPEN-2019-030522 @default.
- Q91889126 P698 31826889 @default.
- Q91889126 P1433 Q17003470 @default.
- Q91889126 P1476 "A prospective, open-label, interventional study protocol to evaluate treatment efficacy of nivolumab based on serum-soluble PD-L1 concentration for patients with metastatic and unresectable renal cell carcinoma" @default.
- Q91889126 P2093 "Masato Fujisawa" @default.
- Q91889126 P2093 "Takashi Omori" @default.
- Q91889126 P2093 "Yukari Bando" @default.
- Q91889126 P2860 Q28131668 @default.
- Q91889126 P2860 Q30235364 @default.
- Q91889126 P2860 Q35113261 @default.
- Q91889126 P2860 Q35619699 @default.
- Q91889126 P2860 Q35796302 @default.
- Q91889126 P2860 Q37530747 @default.
- Q91889126 P2860 Q39511749 @default.
- Q91889126 P2860 Q41316099 @default.
- Q91889126 P2860 Q84014638 @default.
- Q91889126 P2860 Q86570241 @default.
- Q91889126 P304 "e030522" @default.
- Q91889126 P31 Q13442814 @default.
- Q91889126 P356 "10.1136/BMJOPEN-2019-030522" @default.
- Q91889126 P433 "12" @default.
- Q91889126 P478 "9" @default.
- Q91889126 P50 Q41894951 @default.
- Q91889126 P577 "2019-12-10T00:00:00Z" @default.
- Q91889126 P698 "31826889" @default.
- Q91889126 P921 Q111908491 @default.
- Q91889126 P921 Q1164529 @default.
- Q91889126 P932 "6924736" @default.